Articles

P2.18 Responding patients show durable responses to bendamustine in double refractory multiple myeloma patients

BJH - volume 5, issue Abstract Book BHS, january 2014

J. Caers MD, PhD, M.C. Vekemans MD, I. Vande Broek MD, PhD, V. Maertens MD, P.H. Mineur , G. Bries MD, PhD, E. Vandeneste , G. Vanstraelen , K. Beel MD, PhD, F. Leleu , H. Demuynck MD, C. Scheurmans , A. Van De Velde MD, PhD, W. Schroyens MD, PhD, K.L. Wu MD, PhD, N. Meuleman MD, PhD, R. Schots MD, PhD, M. Delforge MD, PhD, C. Doyen MD

Read more

P2.19 Light chain cast nephropathy in a patient with Waldenström’s macroglobulinemia

BJH - volume 5, issue Abstract Book BHS, january 2014

X. Galloo , C. Caron , L. Pipeleers , K. Wissing , K. Fostier MD, F. Trullemans , C. Tielemans , R. Schots MD, PhD, A. De Becker MD

Read more

P2.03 Immunomodulatory Drugs Restore Effector Cell Immune Functions In Myeloma Patients With Low Disease Burden After Autologous Stem Cell Transplantation

BJH - volume 5, issue Abstract Book BHS, january 2014

K. Fostier MD, J. Corthals , C. Heirman , J.L. Aerts , K. Thielemans , R. Schots MD, PhD, B. De Keersmaecker

Read more

P1.06 An unusual presentation of tuberculosis

BJH - volume 5, issue Abstract Book BHS, january 2014

F. Trullemans , R. Mertens , M.C. Chintinne , R. Schots MD, PhD

Read more

O.3 Comparison of 2 nonmyeloablative regimens for allogeneic HCT: a phase II randomized study from the HCT committee of the BHS

BJH - volume 5, issue Abstract Book BHS, january 2014

prof. F. Baron , P. Zachée MD, PhD, J. Maertens MD, PhD, T. Kerre MD, PhD, A. Ory , L. Seidel , C. Graux MD, PhD, P. Lewalle MD, PhD, H. Schouten , K. Theunissen MD, R. Schots MD, PhD, Y. Beguin MD, PhD

Read more

Immunomodulatory drugs: new developments

BJH - volume 4, issue 1, march 2013

K. Fostier MD, A. De Becker MD, R. Schots MD, PhD

Summary

The immunomodulatory drugs (IMiDs) are a class of orally available compounds which are licensed for the treatment of multiple myeloma (thalidomide, lenalidomide) and transfusion-dependent low- and intermediate-risk myelodysplasia (MDS) with deletion of long arm of chromosome 5 (lenalidomide). Pomalidomide, a novel second generation IMiD, is entering clinical trials and seems to further broaden the therapeutic spectrum of these already pleiotropic drugs. Here we summarise new insights into the mechanism of action of IMiDs as well as new developments related to their clinical use, as maintenance therapy in multiple myeloma (MM), in the treatment of myeloproliferative neoplasm- associated myelofibrosis, other types of MDS, chronic lymphocytic leukaemia (CLL) and sickle cell disease (SCD).

(BELG J HEMATOL 2013;1:21–28)

Read more

P.19 Clonaly related monoclonal B-cell lymphocytosis and diffuse large B-cell lymphoma in a patient treated for EBV-positive Hodgkin lymphoma

BJH - 2013, issue BHS Abstractbook, january 2013

C. Caron , A. De Becker MD, K. Fostier MD, M. De Waele , H. De Raeve MD, PhD, R. Schots MD, PhD, F. Trullemans

Read more